BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30664687)

  • 1. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
    Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
    Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXQ1 controls the induced differentiation of melanocytic cells.
    Bagati A; Bianchi-Smiraglia A; Moparthy S; Kolesnikova K; Fink EE; Kolesnikova M; Roll MV; Jowdy P; Wolff DW; Polechetti A; Yun DH; Lipchick BC; Paul LM; Wrazen B; Moparthy K; Mudambi S; Morozevich GE; Georgieva SG; Wang J; Shafirstein G; Liu S; Kandel ES; Berman AE; Box NF; Paragh G; Nikiforov MA
    Cell Death Differ; 2018 Jun; 25(6):1040-1049. PubMed ID: 29463842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
    Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF
    McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
    Elife; 2021 Nov; 10():. PubMed ID: 34812139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
    de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM
    Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
    Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
    Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
    Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
    Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
    Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
    Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
    Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.